Starling Oncology (STLNW) Non-Current Debt (2020 - 2026)

Starling Oncology (STLNW) has reported Non-Current Debt for 6 consecutive years, with $79.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Debt rose 6.46% year-over-year to $79.9 million; the trailing twelve-month figure through Jun 2026 stood at $79.9 million (up 6.46% YoY), and the FY2025 full-year result was $77.4 million, down 16.89% from the prior year.
• Non-Current Debt grew to $79.9 million in Q2 2026 per STLNW's latest filing, from $78.6 million in the prior quarter.
• Across five years, Non-Current Debt topped out at $93.1 million in Q4 2024 and bottomed at $73.9 million in Q1 2025.
• Historically, Non-Current Debt has averaged $82.6 million across 5 years, with a median of $81.4 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Non-Current Debt advanced 7.82% in 2023, then fell 16.89% in 2025.
• Over 5 years, Non-Current Debt stood at $80.6 million in 2022, then grew by 7.7% to $86.8 million in 2023, then climbed by 7.26% to $93.1 million in 2024, then dropped by 16.89% to $77.4 million in 2025, then rose by 3.19% to $79.9 million in 2026.
• According to Business Quant data, Non-Current Debt over the past three periods registered $79.9 million, $78.6 million, and $77.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.